Medifast (MED) Q4 Earnings and Revenues Beat Estimates
Medifast (MED) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of a loss of $0.27 per share. This compares to earnings of $1.09 per share a year ago.
Medifast Launches OPTAVIA ASCEND for Weight Loss Management
MED's new OPTAVIA ASCEND product line combines high-protein meals, fiber-rich nutrients and personalized coaching.
How Should You Play Medifast Stock at a P/E Multiple of 17.6X?
MED is battling customer acquisition challenges and high SG&A costs, while its strategic growth efforts keep it well-positioned for long-term success.
Are Investors Undervaluing MEDIFAST (MED) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Medifast: Earnings Surprise, New AI Technologies, And Extremely Undervalued
Medifast reported better-than-expected quarterly EPS and is investing in new marketing strategies, AI technologies, and supply chain optimization to drive future growth. Despite a decline in the number of coaches and productivity, MED trades close to its book value and continues to generate free cash flow. The company's stock repurchase plan and significant cash reserves indicate confidence in future growth, with a potential valuation target of $78 per share.
MED Q3 Earnings Beat, Revenues Fall on Customer Acquisition Challenges
Medifast's Q3 results lower earnings and revenues, highlighting challenges in customer acquisition. Management issues soft guidance for the fourth quarter.
Medifast (MED) Beats Q3 Earnings and Revenue Estimates
Medifast (MED) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of a loss of $0.15 per share. This compares to earnings of $2.12 per share a year ago.
Medifast, Inc. (MED) Q3 2024 Earnings Call Transcript
Medifast, Inc. (NYSE:MED ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Steven Zenker - Vice President-Investor Relations Dan Chard - Chairman & Chief Executive Officer Jim Maloney - Chief Financial Officer Conference Call Participants Jim Salera - Stephens Inc. Linda Bolton-Weiser - D.A. Davidson Operator Greetings, and welcome to the Medifast Third Quarter 2024 Earnings Conference Call.
Medifast Gears Up for Q3 Earnings: Here's What You Should Know
MED's Q3 results may reflect customer acquisition challenges and a decline in active earning OPTAVIA Coaches due to the increasing adoption of GLP-1 medications.
Medifast Drives Growth With Weight Loss Transformation Strategies
MED is striving to excel in the evolving weight loss market where GLP-1 medication adoption is reshaping the industry dynamics amid macroeconomic challenges.
The Schall Law Firm Encourages Shareholder Participation In A Securities Fraud Inquiry Into Medifast, Inc.
LOS ANGELES, CA / ACCESSWIRE / October 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Medifast Inc Is Being Investigated For Securities Law Violations And Affected Investors Are Invited To Reach Out To The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
